Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omeprazole/sodium bicarbonate powder suspension - Salix Pharmaceuticals

Next Previous
Drug Profile

Omeprazole/sodium bicarbonate powder suspension - Salix Pharmaceuticals

Alternative Names: Acitrel; Omez Insta; Rapinex Powder for Oral Suspension; SAN 05; Zegerid Powder for Oral Suspension

Latest Information Update: 07 Apr 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santarus
  • Developer Norgine; Salix Pharmaceuticals
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Alkalinising agents; Antiulcers; Gastric antisecretories; Small molecules; Sodium compounds
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Gastrointestinal haemorrhage

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 01 Feb 2011 Norgine completes a Phase-I trial in Duodenal ulcer, Erosive oesophagitis and Gastro-oesophageal reflux (in volunteers) in United Kingdom (NCT01710995)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top